Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Archive ouverte

Ducastelle, Sophie | Adès, Lionel | Gardin, Claude | Dombret, Hervé | Prébet, Thomas | Deconinck, Eric | Rio, Bernard | Thomas, Xavier | Debotton, Stephan | Guerci, Agnès | Gratecos, Nicole | Stamatoullas, Aspasia | Fegueux, Nathalie | Dreyfus, François | Fenaux, Pierre, P. | Wattel, Eric

Edité par CCSD ; Ferrata Storti Foundation -

International audience. We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS, autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant. With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion